Home » Posts tagged with » Regeneron Pharmaceuticals
Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2

Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2

US biotech company Regeneron Pharmaceuticals has started the first clinical trial of its investigational dual antibody cocktail REGN-COV2 (REGN10933+REGN10987) for the prevention and treatment of COVID-19. The REGN-COV2 clinical program will feature four separate study populations, which include hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure, […]

Dupixent delivers positive results in eosinophilic esophagitis trial

Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of Part A of a phase 3 trial in patients 12 years and older who have eosinophilic esophagitis (EoE). The late-stage trial also all the key secondary endpoints. Dupixent is now the first and only biologic to demonstrate […]

Continue reading …
Sanofi, Regeneron secure Libtayo EMA approval for a type of skin cancer

Libtayo EMA approval : The European Commission has given conditional approval for Libtayo (cemiplimab) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), which is one of the most commonly diagnosed skin cancers. Libtayo, which is a fully-human monoclonal antibody targeting the immune checkpoint receptor programmed cell death […]

Continue reading …
Praluent bags EC approval to reduce risk of CV events in patients with ASCD

Regeneron Pharmaceuticals and Sanofi have secured approval for Praluent (alirocumab) for a new indication from the European Commission (EC), which is for the reduction of cardiovascular risk in adults with established atherosclerotic CV disease (ASCD) by reducing low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correct other risk factors. Atherosclerotic CV Disease is defined […]

Continue reading …
Sanofi, Regeneron report Dupixent FDA approval for asthma

Dupixent FDA approval : Dupixent (dupilumab), an eczema drug the co-developed by Sanofi and Regeneron Pharmaceuticals, has been approved by the US Food and Drug Administration as an add-on maintenance therapy for two forms of asthma. Dupixent FDA Approval The new Dupixent FDA approval is for treating patients with moderate-to-severe asthma aged 12 years and older […]

Continue reading …
Regeneron secures updated label approval from FDA for EYLEA in wet-AMD

The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) by Regeneron Pharmaceuticals for EYLEA (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD). Regeneron Pharmaceuticals said that the sBLA is supported by second-year data recorded from the phase 3 VIEW 1 and 2 trials in which patients […]

Continue reading …
Teva, Regeneron report positive data for fasinumab in phase 3 osteoarthritis trial

Teva Pharmaceutical Industries and Regeneron Pharmaceuticals said that a phase 3 study evaluating nerve growth factor (NGF) antibody fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip met both co-primary endpoints and all key secondary endpoints. According to the partners, fasinumab-treated patients had faced significantly less pain and had considerably […]

Continue reading …
Dupixent eczema injection gets FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Dupixent eczema injection with that has become the first ever biologic medicine approved for atopic dermatitis treatment in patients whose disease is not managed adequately […]

Continue reading …
Eczema drug Dupixent succeeds in phase 3 atopic dermatitis clinical trial

Atopic dermatitis clinical trial : The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the primary endpoints of a crucial one-year long phase 3 clinical trial in adult patients with uncontrolled moderate-to-severe atopic dermatitis (AD). Update : Dupixent eczema injection gets FDA approval for atopic dermatitis treatment Atopic Dermatitis Clinical Trial […]

Continue reading …